GeoVax Labs Issues Letter to Shareholders

ATLANTA, April 27 /PRNewswire/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, has issued a letter to its shareholders and has added a question and answer section to its website. To view the shareholder letter in its entirety, please follow this link to the Company's website: www.geovax.com.

In the letter, GeoVax Labs President and CEO Robert T. McNally, PhD, updates shareholders on the Company's continued efforts to increase shareholder value through its key initiatives and developments, which include:

• The Company continues to lead in the development of both preventative and therapeutic HIV/AIDS vaccines. Both uses of the vaccine have successfully completed preclinical efficacy testing in non-human primates.

• GeoVax's preventative HIV vaccine candidate has completed Phase 1 clinical trials in humans, and is currently in a Phase 2a clinical trial being conducted and funded by the HIV Vaccine Trials Network (HVTN). Based on current patient enrollment rates, the Company expects this trial to be completed during 2011.  

• GeoVax's therapeutic vaccine candidate has recently been allowed by the US Food and Drug Administration to begin a Phase 1 clinical trial, a major milestone for this program. The clinical trial site is now preparing to initiate the enrollment of volunteers who meet the trial's criteria, recently HIV-infected individuals who started drug treatment during their first year of infection.

• The Company is also conducting preclinical research on the impact of adding adjuvants (immune system stimulants) to its vaccine components to investigate whether they can improve the effectiveness of its vaccine candidates.

• Results of the stockholders meeting on April 13, 2010 to consider motions to amend the Company's Certificate of Incorporation to increase its authorized shares of common stock and to authorize its Board of Directors to consummate a reverse stock split of its common stock. Both motions were passed by overwhelming majorities. More than 85% of the Company's total outstanding shares were voted with approximately 91% of those voting "For" both proposals.

Addressing GeoVax stockholders, Dr. McNally stated: "This is a very exciting time for GeoVax. To keep you, the owners of our company, informed about events, I thought this would be an opportune time to provide an update about where we are in the development of our HIV/AIDS vaccines and the actions we have taken in response to the vote at our recent special stockholders meeting. Thank you for your support and your belief in what GeoVax is doing. The need for the HIV/AIDS vaccines that GeoVax is developing is tremendous. We are grateful to all of you who are helping make this possible."

About GeoVax Labs, Inc.

GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus -- that leads to AIDS) and other infectious agents.  Our goals include developing HIV/AIDS vaccines for global markets, manufacturing and testing these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines have demonstrated the ability to raise anti-HIV immune responses as well as for their safety.  Successful results from all Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will involve 225 participants at sites in the United States and South America.  Recently the FDA granted permission to proceed with a Phase 1 therapeutic trial for individuals infected with HIV.  Long term, we expect that GeoVax will grant manufacturing and distribution rights in several global markets in return for upfront fees, collaborative development agreements, and royalties on sales and distribution revenues. Internal vaccine manufacturing and distribution will also be considered by GeoVax.  For more information, please visit www.geovax.com.

Forward-Looking Statements

Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

SOURCE GeoVax Labs, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED